

## PARP-1在舌鳞癌组织中的表达及意义

王立萍,陈树伟,侯景辉,庄士民,宋明

510060 广州,华南肿瘤学国家重点实验室 中山大学肿瘤防治中心头颈科

### Expression and Significance of Poly (ADP-ribose) Polymerase 1 in Oral Tongue Squamous Cell Carcinoma

Wang Liping,Chen Shuwei,Hou Jinghui,Zhuang Shimin,Song Ming

Department of Head and Neck Surgery,State Key Laboratory of Oncology of South China,Cancer Center,Sun Yat-sen University,Guangzhou 510060,China

- 摘要
- 参考文献
- 相关文章

全文: [PDF \(1927 KB\)](#) [HTML \(1 KB\)](#) 输出: [BibTeX](#) | [EndNote \(RIS\)](#) [背景资料](#)

#### 摘要

#### 目的

检测PARP-1在舌鳞癌中的表达水平,分析与舌鳞癌患者临床病理因素及预后的相关性,初步探讨PARP-1在舌鳞癌的预后价值。方法采用免疫组织化学法检测155例舌鳞癌组织及13例邻近正常舌组织的石蜡组织切片中PARP-1的表达水平,分析PARP-1的表达水平与舌鳞癌患者的临床病理因素及预后的相关性。结果155例舌鳞癌组织中,PARP-1阳性表达率为89.0%(138/155),其中58.1%(90/155)呈高表达,41.9%(65/155)呈低表达;13例邻近正常舌组织均无PARP-1表达,两者比较差异有统计学意义( $\chi^2=64.815, P=0.000$ )。PARP-1的表达水平与患者的T分期( $\chi^2=10.841, P=0.002$ )、N分期( $\chi^2=8.962, P=0.007$ )、病理分期( $\chi^2=17.151, P=0.000$ )呈正相关。PARP-1高表达者总生存时间( $P=0.037$ )与无瘤生存时间( $P=0.026$ )比低表达者短。结论PARP-1可能是促进舌鳞癌发生发展的癌基因,具有预测舌鳞癌预后的临床价值。

关键词: 舌鳞癌 PARP-1 复发 预后

Abstract:

#### Objective

To detect the expression level and prognostic value of poly(ADP-ribose) polymerase 1(PARP-1) in oral tongue squamous cell carcinoma(OTSCC),and to analysis the relationship between PARP-1 expression and the clinicopathologic characteristics and prognosis of patients.MethodsExpression of PARP-1 in 155 paraffin-embedded specimens of OTSCC and 13 paraffin-embedded specimens of adjacent normal tongue mucosa tissues was detected by the immunohistochemical method.The relationship between PARP-1 expression and the clinicopathologic characteristics and prognosis of patients was analyzed.ResultsExpression of PARP-1 was observed in 89.0%(138/155) of 155 OTSCC specimens.Overexpression of PARP-1 was observed in 58.1%(90/155) of the 155 OTSCC Paraffin specimens,while low expression of PARP-1 was 41.9%(65/155).Expression of PARP-1 was not observed in 13 normal tongue specimens.There was a significant difference between the 2 groups ( $\chi^2=64.815, P=0.000$ ).Expression of PARP-1 positively correlated to T stage( $\chi^2=10.841, P=0.002$ ),N stage( $\chi^2=8.962, P=0.007$ ) and pathological stage ( $\chi^2=17.151, P=0.000$ ).The overall survival ( $P=0.037$ ) and disease free survival ( $P=0.026$ ) were shorter in patients with overexpression of PARP-1 .ConclusionPARP-1 may play an important role in carcinogenesis and cancer progression of OTSCC.PARP-1 may have a prognostic value in OTSCC.

Key words: Oral tongue squamous cell carcinoma PARP-1 Recurrence Prognosis

收稿日期: 2011-12-27;

#### 服务

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ E-mail Alert
- ▶ RSS

#### 作者相关文章

- ▶ 王立萍
- ▶ 陈树伟
- ▶ 侯景辉
- ▶ 庄士民
- ▶ 宋明

作者简介: 王立萍(1986-),女,硕士在读,主要从事舌肿瘤的研究

引用本文:

王立萍,陈树伟,侯景辉等. PARP-1在舌鳞癌组织中的表达及意义[J]. 肿瘤防治研究, 2012, 39(8): 957-960.

Wang Liping,Chen Shuwei,Hou Jinghui et al. Expression and Significance of Poly (ADP-ribose) Polymerase 1 in Oral Tongue Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(8): 957-960.

[1]

[1] CCooper JS,Porter K,Mallin K,et al.National Cancer Database report on cancer of the head and

[2]

neck:10-year update [J] .Head Neck,2009,31(6):748-58.

[3]

[2] RRusthoven K,Ballonoff A,Raben D,et al.Poor prognosis in patients with stage I and II oral tongue

[4]

squamous cell carcinoma [J] .Cancer,2008,112(2):345-51.

[5]

[3] RRusthoven KE,Raben D,Song JI,et al.Survival and patterns of relapse in patients with oral tongue

[6]

cancer [J] .J Oral Maxillofac Surg,2010,68(3):584-9.

[7]

[4] JJagtap P,Szabó C.Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

[8]

[J] .Nat Rev Drug Discov,2005,4(5):421-40.

[9]

[5] WWoodhouse BC,Dianov GL.Poly ADP-ribose polymerase-1:an international molecule of mystery [J] .DNA

[10]

Repair (Amst),2008,7(7):1077-86.

[11]

[6] SStaibano S,Pepe S,Lo Muzio L,et al.Poly(adenosine diphosphate-ribose) polymerase 1 expression in

[12]

malignant melanomas from photoexposed areas of the head and neck region [J] .Hum Pathol,2005,36

[13]

[7] ::724-31.

[14]

[7] AAlli E,Sharma VB,Sunderesakumar P,et al.Defective repair of oxidative dna damage in triple-

[15]

negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase [J] .Cancer

[16]

Res,2009,69(8):3589-96.

[17]

[8] SShimizu S,Nomura F,Tomonaga T,et al.Expression of poly(ADP-ribose) polymerase in human

[18]

hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance

[19]

[J] .Oncol Rep,2004,12(4):821-5.

[20]

[9] GGhabreau L,Roux JP,Frappart PO,et al.Poly(ADP-ribose) polymerase-1,a novel partner of

[21]

progesterone receptors in endometrial cancer and its precursors [J].Int J Cancer,2004,109(3):317-21.

[22]

[10] Noshio K,Yamamoto H,Mikami M,et al.Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in

[23]

the early stage of colorectal carcinogenesis [J].Eur J Cancer,2006,42(14):2374-81.

[24]

[11] Radovits T,Lin LN,Zotkina J,et al.Poly(ADP-ribose) polymerase inhibition improves endothelial

[25]

dysfunction induced by reactive oxidant hydrogen peroxide in vitro [J].Eur J Pharmacol,2007,564(1-

[26] 3]:1:158-66.

[27]

[12] Noren Hooten N,Kompaniez K,Barnes J,et al.Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-

[28]

oxoguanine-DNA glycosylase (OGG1) [J].J Biol Chem,2011,286(52): 44679-90.

[29]

[13] Nguyen D,Zajac-Kaye M,Rubinstein L,et al.Poly(ADP-ribose) polymerase inhibition enhances p53-

[30]

dependent and -independent DNA damage responses induced by DNA damaging agent [J].Cell Cycle,2011,10

[31]

:4074-82.

[32]

[14] Brustmann H.Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian

[33]

carcinoma:correlation with p53,MIB-1, and outcome [J].Int J Gynecol Pathol,2007,26(2):147-53.

[34]

[15] Rajaei-Behbahani N,Schmezer P,Ramroth H,et al.Reduced poly(ADP-ribosylation) in lymphocytes of

[35]

laryngeal cancer patients:results of a case-control study [J].Int J Cancer,2002,98(5): 780-4.

[1] 龚丽,欧阳文,秦倩. 阿片类药物与肿瘤复发相关机制研究进展[J]. 肿瘤防治研究, 2012, 39(9): 1153-1155.

[2] 蔡鸿宁, 张蕾, 张敦兰, 高晗, 罗俊. 人工神经网络在宫颈癌预后预测中的应用[J]. 肿瘤防治研究, 2012, 39(9): 1117-1119.

[3] 郭伟祥,汤丽娜,何爱娜,沈赞,姚阳. 吡喃阿霉素为基础的两药联合方案治疗复发或耐药骨肉瘤临床研究[J]. 肿瘤防治研究, 2012, 39(9): 1128-1131.

[4] 郑刚, 王舒艺, 熊斌. 循环癌细胞和胃癌预后关系的Meta分析[J]. 肿瘤防治研究, 2012, 39(9): 1139-1145.

[5] 张金磊, 杨祚璋. Ezrin与骨巨细胞瘤侵袭转移机制的关系[J]. 肿瘤防治研究, 2012, 39(9): 1156-1159.

[6] 马向涛. 外科医师手术量对直肠癌患者并发症与预后的影响[J]. 肿瘤防治研究, 2012, 39(8): 903-905.

[7] 兰桂萍,司勇锋,翁敬锦,韦海明,覃扬达,何宁. p53和p21WAF1在鼻咽癌rAd-p53瘤内注射前后的表达及其与近期预后的关系[J]. 肿瘤防治研究, 2012, 39(8): 961-965.

[8] 王玉祥,王军,祝淑钗,田丹丹,吕冬捷,王袆,乔学英. 老年食管癌三维适形与调强放射治疗疗效比较[J]. 肿瘤防治研究, 2012, 39(8): 1008-1013.

[9] 卢艳,姚德生. 复发性宫颈癌的手术治疗进展[J]. 肿瘤防治研究, 2012, 39(7): 872-875.

[10] 丁晓燕, 樊英, 马飞, 李青, 王佳玉, 袁梵, 张频, 徐兵河. 绝经后乳腺癌骨转移患者骨相关事件及预后分析[J]. 肿瘤防治研究, 2012, 39(6): 627-631.

[11] 李香丹, 杨文涛, 孙抒, 金香子, 崔明花. 乳腺实性乳头状瘤中Ki67的表达及临床意义[J]. 肿瘤防治研究, 2012, 39(6): 762-763.

[12] 别志欣综述, 李琳审校. MicroRNA在非小细胞肺癌中的研究进展[J]. 肿瘤防治研究, 2012, 39(6): 739-743.

[13] 李星, 龚益平, 熊斌. 三阴性乳腺癌的临床病理特征及预后分析[J]. 肿瘤防治研究, 2012, 39(5): 535-537.

[14] 段孝凤, 高晓旭, 顾宪文. 食管癌术后颈部淋巴转移复发76例临床分析[J]. 肿瘤防治研究, 2012, 39(5): 563-566.

[15] 邵丰, 杨如松, 邹卫, 赵一听, 刘政呈, 马国栋, 曹珲, 潘宴青, 王尊乔. I 期非小细胞肺癌术前与术后血清癌胚抗原浓度变化与预后的相关性分析[J]. 肿瘤防治研究, 2012, 39(5): 586-588.